

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-29 (canceled).

30. (Currently amended) A method for the diagnosis of tumors, comprising
obtaining a sample from a subject suspected of containing tumor cells,
contacting said sample with an antibody or an antigen-binding fragment
thereof, which ~~discriminates between uPAR on normal and tumor cells,~~ and binds
to the epitope 52-60 of the human urokinase receptor (uPAR), wherein a binding
of the antibody or the antigen-binding fragment thereof with tumor cells in the
sample is indicative of a tumor and gives a prognosis for the ~~cause~~ course of a
malignant disease in said subject.

31. (Previously presented) The method according to claim 30, wherein said
tumor cells are disseminated tumor cells in bone marrow.

32. (Previously presented) The method according to claim 30, wherein said
sample is contacted with said antibody or an antigen-binding fragment in an
ELISA.

33. (Previously presented) The method according to claim 30, wherein said binding of the antibody or the antigen-binding fragment thereof with tumor cells is determined in a double-fluorescence detection method.

34. (Previously presented) The method according to claim 30, wherein said antibody is the monoclonal antibody IIIF10, or antigen binding fragments thereof has the same binding specificity as monoclonal antibody IIIF10, or an antibody or antibody fragment having a binding specificity to the epitope 52-60 of uPAR.

35. (Previously presented) The method according to claim 34, wherein said antibody comprises

(a) a CDR3-VH amino acid sequence (I)

D G S M G G F D Y (SEQ ID NO:5), and/or

(b) a CDR3-VL amino acid sequence (II)

L Q H W N Y P Y T (SEQ ID NO:6),

(c) a CDR1-VH amino acid sequence

S Y D I N (SEQ ID NO:7),

(d) a CDR1-VL amino acid sequence

K A S Q N V R T T V A (SEQ ID NO: 8),

(e) a CDR2-VH amino acid sequence

W I F P G D G S T N Y N E K F K D (SEQ ID NO: 9), and

(f) a CDR2-VL amino acid sequence

L A S N R H T (SEQ ID NO: 10).

36. (Withdrawn) A recombinant polypeptide which has antibody properties, comprising

(a) a CDR3-VH amino acid sequence (I)

D G S M G G F D Y (SEQ ID NO:5), and/or

(b) a CDR3-VL amino acid sequence (II)

L Q H W N Y P Y T (SEQ ID NO:6).

37. (Withdrawn) The recombinant polypeptide according to claim 36, wherein said polypeptide is an scFv antibody fragment.

38. (Withdrawn) The recombinant polypeptide according to claim 36, wherein said polypeptide is a humanized antibody fragment.

39. (Withdrawn) The recombinant polypeptide according to claim 36, wherein said polypeptide is coupled to an effector group.

40. (New) The method according to claim 30, further comprising contacting a second sample from said subject with a second antibody or an antigen-binding fragment thereof, which binds to a different epitope of the human urokinase receptor (uPAR), and comparing the binding of the different antibodies, wherein a difference in the binding of the two antibodies is indicative of a tumor and gives a prognosis for the course of a malignant disease in said subject.